Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms

키워드

참고문헌 (31)

1. Swerdlow S, "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", IARC, ~ (2008)
2. Cankovic M, "Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods", Am J Clin Pathol, 132, pp.713~721 (2009)[DOI]
3. Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)[DOI]
4. Steensma DP, "The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes", Blood, 106, pp.1207~1209 (2005)[DOI]
5. Busque L, "Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian Mpn Group", Am J Clin Pathol, 146, pp.408~422 (2016)[DOI]
6. Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)[DOI]
7. Passamonti F, "Clinical relevance of JAK2 (V617F) mutant allele burden", Haematologica, 94, pp.7~10 (2009)[DOI]
8. Borowczyk M, "The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms", Thromb Res, 135, pp.272~280 (2015)[DOI]
9. Campbell PJ, "V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis", Blood, 107, pp.2098~2100 (2006)[DOI]
10. Koren-Michowitz M, "JAK2 V617F allele burden is associated with transformation to myelofibrosis", Leuk Lymphoma, 53, pp.2210~2213 (2012)[DOI]
11. Tefferi A, "Low JAK2 V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival", Leukemia, 22, pp.756~761 (2008)[DOI]
12. Kinz E, "Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR", Int J Lab Hematol, 37, pp.217~224 (2015)[DOI]
13. Bench AJ, "Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations", Br J Haematol, 160, pp.25~34 (2013)[DOI]
14. Sanmamed MF, "Quantitative cell-free circulating BRAF V600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors", Clin Chem, 61, pp.297~304 (2015)[DOI]
15. Hindson BJ, "High-throughput droplet digital PCR system for absolute quantitation of DNA copy number", Anal Chem, 83, pp.8604~8610 (2011)[DOI]
16. Zhang Y, "Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR", Oncotarget, 8, pp.5861~5873 (2017)
17. Otsuji K, "Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients", Breast Cancer Res Treat, 162, pp.11~18 (2017)[DOI]
18. Kim HR, "Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms", PLoS One, 8, pp.e52518~ (2013)[DOI]
19. Waterhouse M, "Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR", Ann Hematol, 95, pp.739~744 (2016)[DOI]
20. Reid AL, "Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR", Clin Biochem, 48, pp.999~1002 (2015)[DOI]
21. Watanabe M, "Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR", Clin Cancer Res, 21, pp.3552~3560 (2015)[DOI]
22. Lange T, "JAK2 V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse", Haematologica, 98, pp.722~728 (2013)[DOI]
23. Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", The Lancet, 365, pp.1054~1061 (2005)[DOI]
24. Benati M, "Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms", Clin Chem Lab Med, 53, pp.1005~1011 (2015)
25. Passamonti F, "A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications", Leukemia, 24, pp.1574~1579 (2010)[DOI]
26. Alshemmari SH, "JAK2 V617F allele burden in patients with myeloproliferative neoplasms", Ann Hematol, 93, pp.791~796 (2014)[DOI]
27. Jones AV, "Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha", Blood, 107, pp.3339~3341 (2006)[DOI]
28. Vannucchi AM, "Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia", Blood, 110, pp.840~846 (2007)[DOI]
29. Cervantes F, "Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis", Blood, 122, pp.4047~4053 (2013)[DOI]
30. Cervantes F, "Does ruxolitinib prolong the survival of patients with myelofibrosis?", Blood (2016)
31. Vannucchi AM, "Ruxolitinib versus standard therapy for the treatment of polycythemia vera", N Engl J Med, 372, pp.426~435 (2015)[DOI]

관련 논문AI추천